fbpx

The Max Foundation is proud to announce it has signed a renewed collaboration agreement with Incyte – a dedicated pharmaceutical partner and member of our humanitarian pact.

Since February 2017, Incyte has partnered with The Max Foundation to assist patients with cancer in Central Asia and Eastern Europe who are in need and unable to access treatment. The renewal by Incyte will allow The Max Foundation, through our drug donation program Max Access Solutions, to expand the number of patients who may be eligible to receive treatment with Iclusig (ponatinib) from 35 to up to 50 at no cost for as long as needed.

“As we work to expand treatment access for patients in low-income countries, we are grateful to have committed partners like Incyte,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “We’re so excited to not only continue our collaboration, but also to expand its size and bring effective medicine to more patients in need.”

“At Incyte we are fully aligned with the mission of The Max Foundation, focused on increasing patient access to care, support, and treatment,” added Jonathan Dickinson, General Manager of Incyte in Europe. “We are proud to be part of a program dedicated to making cancer treatments available to appropriate patients in Central Asia and Eastern Europe. We are happy and privileged to partner with and support to The Max Foundation’s efforts and look forward to another year of making a difference for patients with cancer.”

We at The Max Foundation express our thanks to Incyte for their continued collaboration, and will keep an ear out for the Incyte Bell (pictured below, and rung once each week for each new patient treated).

Raise a cup, drink to a cause

You're invited to Chai for Cancer Seattle on April 29th! Join us for refreshments, entertainment, and community building, aimed at raising awareness for patients coping with cancers that require lifelong treatment and care. Attendance is free, RSVPs encouraged.

RSVP for Chai for Cancer

chai for cancer

This will close in 0 seconds